Grant: Discovery Grants Program - Individual
École Polytechnique de Montréal
$60,500.00
Development of cost-effective and robust manufacturing processes for VLP-based vaccines
FY 2011-12
Summary
Over the past 200 years, vaccination has been one of the most important medical interventions for preventing diseases that has been implemented on a wide scale. New vaccination strategies and new manufacturing technologies have broadened the vaccine market from traditionally pediatric population to a larger population including adults to target, for example, cancer and other chronic diseases. Amongst the vaccine candidates, Viral Like Particles (VLP) have shown great promises for the development of new class of vaccines. VLPs or empty shells of viruses devoid of any genetic material are not infectious and do not replicate, thereby representing a safer alternative than inactivated or attenuated virus-based vaccinations. Because of repeated motifs and surface antigen exposure, they also have an advantage over soluble antigen vaccinations. Safety and potency of vaccines are primary requirements, however to allow access to large population, especially in low-income countries, cost-effective manufacturing is of critical importance. Therefore, efficient production systems exploiting advances in recombinant DNA and cell culture technologies are highly needed. The baculovirus expression system using insect cell culture has been extensively and successfully used in our lab over the past 15 years to produce large quantities of recombinant proteins, but also complex viral structures such as adeno-associated viruses. We now have at hand a powerful insect-cell based expression system, generic tools and the appropriate facilities but above all, an established expertise. In order to build on our existing expertise, and for the purpose of advancing the science of VLP processing, and contributing to the global effort against infectious diseases we propose a research program which will focus on addressing the upstream and downstream limitations to the development of cost-effective and robust manufacturing processes for VLP-based vaccines. This project will have far-reaching consequences. It will lead to the development of an integrated and robust high yield process for Influenza-VLP-vaccine and will constitute a model that will be applicable to all VLP-based vaccines.
Program
Discovery Grants Program - Individual
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
261596-2009
Name nom
Kamen, Amine
Department département
Génie chimique
Organization id
64
Institution établissement
École Polytechnique de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2009
Award amount
60500
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
4
Committee name en
Chem. & Metallurgical Eng.
Committee name fr
Génies chimique et métal.
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Partie
3
Nb partie
5
Application title
Development of cost-effective and robust manufacturing processes for VLP-based vaccines
Keyword
NSERC
Application summary
Over the past 200 years, vaccination has been one of the most important medical interventions for preventing diseases that has been implemented on a wide scale. New vaccination strategies and new manufacturing technologies have broadened the vaccine market from traditionally pediatric population to a larger population including adults to target, for example, cancer and other chronic diseases. Amongst the vaccine candidates, Viral Like Particles (VLP) have shown great promises for the development of new class of vaccines. VLPs or empty shells of viruses devoid of any genetic material are not infectious and do not replicate, thereby representing a safer alternative than inactivated or attenuated virus-based vaccinations. Because of repeated motifs and surface antigen exposure, they also have an advantage over soluble antigen vaccinations. Safety and potency of vaccines are primary requirements, however to allow access to large population, especially in low-income countries, cost-effective manufacturing is of critical importance. Therefore, efficient production systems exploiting advances in recombinant DNA and cell culture technologies are highly needed. The baculovirus expression system using insect cell culture has been extensively and successfully used in our lab over the past 15 years to produce large quantities of recombinant proteins, but also complex viral structures such as adeno-associated viruses. We now have at hand a powerful insect-cell based expression system, generic tools and the appropriate facilities but above all, an established expertise. In order to build on our existing expertise, and for the purpose of advancing the science of VLP processing, and contributing to the global effort against infectious diseases we propose a research program which will focus on addressing the upstream and downstream limitations to the development of cost-effective and robust manufacturing processes for VLP-based vaccines. This project will have far-reaching consequences. It will lead to the development of an integrated and robust high yield process for Influenza-VLP-vaccine and will constitute a model that will be applicable to all VLP-based vaccines.